Six months after Biogen stopped work on a closely watched experimental Alzheimer’s disease treatment, the neuroscience drug developer is reviving it with plans to file for FDA approval.

Aducanumab’s Phase 3 failure in March was viewed as yet another nail in the coffin for the so-called “amyloid hypothesis”—the theory that by breaking up or clearing the buildup of amyloid protein in the brain, a therapy could stop or even reverse the decline of patients’ memory loss.

But on Tuesday Biogen (NASDAQ: BIIB) and Japan’s Eisai, which have been collaborating to advance the drug as a potential treatment for early Alzhiemer’s Read more »